Inhaled brochodilators for acute chest syndrome in people with sickle cell disease

Sickle Cell Unit, Tropical Medicine Research Institute, Kingston 7, Jamaica. .
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 07/2012; 7(7):CD003733. DOI: 10.1002/14651858.CD003733.pub2
Source: PubMed


Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome.
To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome.
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and EMBASE (1981 to 2002).Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 15 March 2012.
Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.
We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.

29 Reads
  • Source
    • "Case reports of asthma-related deaths have also been described [28]. Strong evidence is accumulating from multiple investigators and centers that asthma is an independent risk factor for early mortality in both adults and children with SCD [15, 18, 22, 27, 29], yet no randomized controlled trials of asthma therapies in SCD have been published to date [30]. Since asthma is a modifiable risk factor, effective asthma management may ultimately impact morbidity and mortality in SCD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is a common comorbid factor in sickle cell disease (SCD). However, the incidence of asthma in SCD is much higher than expected compared to rates in the general population. Whether "asthma" in SCD is purely related to genetic and environmental factors or rather is the consequence of the underlying hemolytic and inflammatory state is a topic of recent debate. Regardless of the etiology, hypoxemia induced by bronchoconstriction and inflammation associated with asthma exacerbations will contribute to a cycle of sickling and subsequent complications of SCD. Recent studies confirm that asthma predisposes to complications of SCD such as pain crises, acute chest syndrome, and stroke and is associated with increased mortality. Early recognition and aggressive standard of care management of asthma may prevent serious pulmonary complications and reduce mortality. However, data regarding the management of asthma in SCD is very limited. Clinical trials are needed to evaluate the effectiveness of current asthma therapy in patients with SCD and coincident asthma, while mechanistic studies are needed to delineate the underlying pathophysiology.
    Full-text · Article · Nov 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apheresis is the process of separating the blood and removing or manipulating a cellular or plasma component for therapeutic benefit. Such procedures may be indicated in the critical care setting as primary or adjunctive therapy for certain hematologic, neurologic, renal, and autoimmune/rheumatologic disorders. In part I of this series, the technical aspects of apheresis were described and the physiologic rationale and clinical considerations were discussed. This review highlights the pathophysiologic basis, specific clinical indications, and treatment parameters for disorders that more commonly require management in the intensive care unit. The choice of plasma or cellular apheresis in these cases is guided by well-accepted, evidence-based clinical treatment guidelines. For some disorders, such as liver failure, severe sepsis, and multiple-organ dysfunction syndrome, apheresis treatment approaches remain experimental. Ongoing studies are investigating the potential utility of conventional plasma exchange, ex vivo plasma manipulation, and newer technologies for these and other disorders in severely ill patients.
    No preview · Article · Mar 2005 · Journal of Intensive Care Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: The numbers of patients with sickle cell disease in Northern Europe are steadily increasing due to migration, leading to a need for improved healthcare services for these patients. We outline the role of neonatal and antenatal screening programmes in the diagnosis of sickle cell disease, clinical aspects of care and the therapeutic options available. The clinical areas discussed in detail are pain management, the management of stroke and other neurological complications and the management of pulmonary and splenic complications. The role of hydroxyurea, blood transfusion and bone marrow transplantation are also discussed.
    No preview · Article · Feb 2007 · Scandinavian Journal of Clinical and Laboratory Investigation
Show more